Mizuho Securities analyst Difei Yang maintained a Buy rating on Viewray (VRAY) on July 15 and set a price target of $12. The company’s shares closed yesterday at $9.15.
According to TipRanks.com, Yang is a 4-star analyst with an average return of 9.1% and a 41.5% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals Inc, Alder Biopharmaceuticals, and Audentes Therapeutics.
Currently, the analyst consensus on Viewray is a Strong Buy with an average price target of $13.67, representing a 49.4% upside. In a report issued on July 10, Northland Securities also assigned a Buy rating to the stock with a $20 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $13.21 and a one-year low of $4.86. Currently, Viewray has an average volume of 892.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ViewRay, Inc. engages in the design, manufacture and market magnetic resonance imaging (MRI) system. It develops MRIdian to address the key limitations of existing external-beam radiation therapy technologies, and employs MRI-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue, and other critical organs, both before and during radiation treatment delivery. The company was founded by Dinara Akzhigitova on September 6, 2013 and is headquartered in Oakwood Village, OH.
